Back to GetFilings.com



Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934

For the quarterly period ended March 31, 2004

Commission File No.: 001-8833

HealthStream, Inc.

(Exact name of registrant as specified in its charter)
     
Tennessee   62-1443555

 
 
 
(State or other jurisdiction of   (I.R.S. Employer Identification No.)
incorporation or organization)    
     
209 10th Avenue South, Suite 450    
Nashville, Tennessee   37203

 
 
 
(Address of principal executive offices)   (Zip Code)

(615) 301-3100


(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 11, 2004, 20,560,012 shares of the registrant’s common stock were outstanding.


Index to Form 10-Q

HEALTHSTREAM, INC.

             
        Page
        Number
  Financial Information        
  Financial Statements        
      1  
      2  
      3  
      4  
  Notes to Condensed Consolidated Financial Statements     5  
  Management’s Discussion and Analysis of Financial Condition and Results of Operations     8  
  Quantitative and Qualitative Disclosures About Market Risk     13  
  Controls and Procedures     13  
  Other Information        
  Exhibits and Reports on Form 8-K     13  
  Signature     14  
 EX-31.1 SECTION 302 CERTIFICATION OF THE CEO
 EX-31.2 SECTION 302 CERTIFICATION OF THE CFO
 EX-32.1 SECTION 906 CERTIFICATION OF THE CEO
 EX-32.2 SECTION 906 CERTIFICATION OF THE CFO

 


Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS
                 
    March 31,   December 31,
    2004
  2003
    (Unaudited)   (Note 1)
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 13,809,441     $ 14,219,807  
Investments in short term marketable securities
    2,512,765       2,957,703  
Restricted cash
    308,432       723,878  
Interest receivable
    213,471       119,263  
Accounts receivable, net of allowance for doubtful accounts of $256,645 at March 31, 2004 and $278,502 at December 31, 2003, respectively
    3,016,851       2,497,997  
Accounts receivable - unbilled
    587,677       592,538  
Prepaid development fees, net of amortization
    379,302       238,566  
Other prepaid expenses and other current assets
    765,406       805,970  
 
   
 
     
 
 
Total current assets
    21,593,345       22,155,722  
Property and equipment:
               
Furniture and fixtures
    921,115       920,724  
Equipment
    5,420,360       4,896,395  
Leasehold improvements
    1,240,201       1,239,353  
 
   
 
     
 
 
 
    7,581,676       7,056,472  
Less accumulated depreciation and amortization
    (5,260,662 )     (5,053,530 )
 
   
 
     
 
 
 
    2,321,014       2,002,942  
Goodwill
    3,306,688       3,306,688  
Intangible assets, net of accumulated amortization of $6,466,206 at March 31, 2004 and $6,351,860 at December 31, 2003, respectively
    415,936       510,282  
Notes receivable - related party
    233,003       233,003  
Other assets
    157,632       190,006  
 
   
 
     
 
 
Total assets
  $ 28,027,618     $ 28,398,643  
 
   
 
     
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
Current liabilities:
               
Accounts payable
  $ 829,404     $ 864,977  
Accrued liabilities
    1,119,542       967,995  
Accrued compensation and related expenses
    165,215       172,950  
Registration liabilities
    305,422       735,265  
Deferred revenue
    3,450,286       3,059,248  
Current portion of capital lease obligations
    22,258       39,020  
 
   
 
     
 
 
Total current liabilities
    5,892,127       5,839,455  
Capital lease obligations, less current portion
          1,199  
Commitments and contingencies
           
Shareholders’ equity:
               
Common stock, no par value, 75,000,000 shares authorized; 20,455,996 and 20,455,746 shares issued and outstanding at March 31, 2004 and December 31, 2003, respectively
    91,417,163       91,416,853  
Accumulated other comprehensive income
    1,635       5,475  
Accumulated deficit
    (69,283,307 )     (68,864,339 )
 
   
 
     
 
 
Total shareholders’ equity
    22,135,491       22,557,989  
 
   
 
     
 
 
Total liabilities and shareholders’ equity
  $ 28,027,618     $ 28,398,643  
 
   
 
     
 
 

See accompanying notes to the condensed consolidated financial statements.

1


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
                 
    Three Months Ended March 31,
    2004
  2003
Revenues, net
  $ 4,907,772     $ 4,416,709  
Operating costs and expenses:
               
Cost of revenues
    1,890,073       1,495,488  
Product development
    647,002       955,460  
Sales and marketing
    1,156,953       1,128,855  
Depreciation
    313,807       376,576  
Amortization of intangibles, content fees, fixed royalties, and prepaid compensation
    173,813       519,871  
Other general and administrative expenses
    1,194,639       1,422,731  
 
   
 
     
 
 
Total operating costs and expenses
    5,376,287       5,898,981  
Loss from operations
    (468,515 )     (1,482,272 )
Other income (expense):
               
Interest and other income
    55,224       129,309  
Interest and other expense
    (5,677 )     (6,477 )
 
   
 
     
 
 
 
    49,547       122,832  
 
   
 
     
 
 
Net loss
  $ (418,968 )   $ (1,359,440 )
 
   
 
     
 
 
Net loss per share:
               
Basic and diluted net loss per share
  $ (0.02 )   $ (0.07 )
 
   
 
     
 
 
Weighted average shares of common stock outstanding:
               
Basic and diluted
    20,446,544       20,306,364  
 
   
 
     
 
 

See accompanying notes to the condensed consolidated financial statements.

2


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY (UNAUDITED)
THREE MONTHS ENDED MARCH 31, 2004
                                         
    Common Stock   Accumulated   Other
Comprehensive
  Total
Shareholders’
    Shares
  Amount
  Deficit
  Income
  Equity
Balance at December 31, 2003
    20,455,746     $ 91,416,853     $ (68,864,339 )   $ 5,475     $ 22,557,989  
Net loss
                (418,968 )           (418,968 )
Unrealized loss on investments, net of tax
                      (3,840 )     (3,840 )
 
                                   
 
 
Comprehensive loss
                            (422,808 )
Exercise of stock options
    250       310                   310  
 
   
 
     
 
     
 
     
 
     
 
 
Balance at March 31, 2004
    20,455,996     $ 91,417,163     $ (69,283,307 )   $ 1,635     $ 22,135,491  
 
   
 
     
 
     
 
     
 
     
 
 

See accompanying notes to the condensed consolidated financial statements.

3


Table of Contents

HEALTHSTREAM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
                 
    Three Months Ended March 31,
    2004
  2003
OPERATING ACTIVITIES:
               
Net loss
  $ (418,968 )   $ (1,359,440 )
Adjustments to reconcile net loss to net cash used in operating activities:
               
Depreciation
    313,807       376,576  
Amortization of intangibles, content fees, fixed royalties, and prepaid compensation
    173,813       519,871  
Provision for doubtful accounts
    15,000       40,000  
Realized loss on disposal of property & equipment
    3,703       2,202  
Changes in operating assets and liabilities:
               
Accounts and unbilled receivables
    (528,993 )     (403,430 )
Restricted cash
    415,446       360,331  
Interest receivable
    (94,208 )     94,066  
Prepaid development fees
    (184,266 )     (34,629 )
Other prepaid expenses and other current assets
    22,252       (207,660 )
Other assets
    46,660       116,467  
Accounts payable
    (35,573 )     649,164  
Accrued liabilities and compensation
    143,812       (766,273 )
Registration liabilities
    (429,843 )     (348,729 )
Deferred revenue
    391,038       288,868  
 
   
 
     
 
 
Net cash used in operating activities
    (166,320 )     (672,616 )
INVESTING ACTIVITIES:
               
Proceeds from maturities and sales of investments in marketable securities
    2,945,000       3,450,000  
Purchase of investments in marketable securities
    (2,535,811 )      
Purchase of property and equipment
    (635,584 )     (277,536 )
 
   
 
     
 
 
Net cash (used in) provided by investing activities
    (226,395 )     3,172,464  
FINANCING ACTIVITIES:
               
Exercise of stock options
    310        
Payments on capital lease obligations
    (17,961 )     (28,196 )
 
   
 
     
 
 
Net cash used in financing activities
    (17,651 )     (28,196 )
Net (decrease) increase in cash and cash equivalents
    (410,366 )     2,471,652  
Cash and cash equivalents at beginning of period
    14,219,807       4,069,631  
 
   
 
     
 
 
Cash and cash equivalents at end of period
  $ 13,809,441     $ 6,541,283  
 
   
 
     
 
 
SUPPLEMENTAL CASH FLOW INFORMATION:
               
Interest paid
  $ 3,484     $ 4,430  
 
   
 
     
 
 

See accompanying notes to the condensed consolidated financial statements.

4


Table of Contents

HEALTHSTREAM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, condensed consolidated financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated in consolidation. Operating results for the three months ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.

The balance sheet at December 31, 2003 is consistent with the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for a complete set of financial statements. For further information, refer to the consolidated financial statements and footnotes thereto for the year ended December 31, 2003 (included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission).

2. RECENT ACCOUNTING PRONOUNCEMENTS

In January 2003, the Financial Accounting Standards Board (FASB) issued FIN 46, “Consolidation of Variable Interest Entities,” to expand upon and strengthen existing accounting guidance that addresses when a company should include in its financial statements the assets, liabilities and activities of another entity. Prior to the effective date of FIN 46, a company generally had included another entity in its consolidated financial statements only if it controlled the entity through voting interests. FIN 46 changed that guidance by requiring a variable interest entity, as defined, to be consolidated by a company if that company is subject to a majority of the risk of loss from the variable interest entity’s activities or is entitled to receive a majority of the entity’s residual returns or both. FIN 46 also requires disclosure about variable interest entities that the company is not required to consolidate but in which it has a significant variable interest. The consolidation requirements of FIN 46 apply immediately to variable interest entities created after January 31, 2003 and in the first fiscal year or interim period ending after March 15, 2004 for entities created before January 31, 2003. The adoption of FIN 46 did not have any impact on our consolidated financial position or results of operations.

3. STOCK-BASED COMPENSATION

We account for our stock-based compensation plans under the intrinsic value-based method of accounting prescribed by Accounting Principles Board Opinion No. 25 “Accounting for Stock Issued to Employees” (APB 25) and related interpretations. APB 25 does not utilize the fair value method, as prescribed by SFAS No. 123, “Accounting for Stock-Based Compensation” (SFAS No. 123). However, we have disclosed the fair value recognition requirements of SFAS No. 123 and the additional disclosure requirements as specified in SFAS No.148, “Accounting for Stock-Based Compensation-Transition and Disclosure,” which amended SFAS No. 123.

If the alternative method of accounting for stock incentive plans prescribed by SFAS No. 123 had been followed, our net loss and net loss per share would have been as follows:

                 
    Three Months Ended
    March 31, 2004
  March 31, 2003
Net loss as reported
  $ (418,968 )   $ (1,359,440 )
Add: Stock-based employee compensation expense included in reported net loss, net of related taxes
           
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards net of related tax effects
    (115,950 )     (144,604 )
 
   
 
     
 
 
Pro forma net loss
  $ (534,918 )   $ (1,504,044 )
 
   
 
     
 
 
Basic and diluted net loss per share – as reported
  $ (0.02 )   $ (0.07 )
 
   
 
     
 
 
Basic and diluted net loss per share – pro forma
  $ (0.03 )   $ (0.07 )
 
   
 
     
 
 

5


Table of Contents

HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

4. NET LOSS PER SHARE

Basic net loss per share is computed by dividing the net loss available to common shareholders for the period by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted average number of common and common equivalent shares outstanding during the period. Common equivalent shares, composed of incremental common shares issuable upon the exercise of stock options and warrants, and escrowed or restricted shares, are included in diluted net loss per share only to the extent these shares are dilutive. The total number of common equivalent shares excluded from the calculations of diluted net loss per share, due to their anti-dilutive effect, was approximately 3,400,000 and 3,100,000 at March 31, 2004 and 2003, respectively.

5. BUSINESS SEGMENTS

We have two reportable segments, services provided to healthcare organizations and professionals (HCO) and services provided to pharmaceutical and medical device companies (PMD). The accounting policies of the segments are the same as those described in the summary of significant accounting policies in our Annual Report on Form 10-K for the year ended December 31, 2003. We manage and operate our business segments based on the markets they serve and the products and services provided to those markets.

The following is our business segment information as of and for the three months ended March 31, 2004 and 2003. We measure segment performance based on the operating loss before income taxes and prior to the allocation of corporate overhead expenses, interest income, interest expense, and depreciation.

                 
    Three months ended
    March 31, 2004
  March 31, 2003
Revenues
               
HCO
  $ 3,216,744     $ 2,879,231  
PMD
    1,691,028       1,537,478  
 
   
 
     
 
 
Total net revenue
  $ 4,907,772     $ 4,416,709  
 
   
 
     
 
 
Income (Loss) from operations
               
HCO
  $ 1,102,977     $ 545,652  
PMD
    110,099       (66,014 )
Unallocated
    (1,681,591 )     (1,961,910 )
 
   
 
     
 
 
Total loss from operations
  $ (468,515 )   $ (1,482,272 )
 
   
 
     
 
 
Segment Assets
               
HCO *
  $ 5,158,845     $ 5,902,044  
PMD *
    4,596,121       5,227,555  
Unallocated
    18,272,652       20,207,453  
 
   
 
     
 
 
Total assets
  $ 28,027,618     $ 31,337,052  
 
   
 
     
 
 

* Segment assets include restricted cash, accounts and unbilled receivables, prepaid and other current assets, other assets, property and equipment, and intangible assets. Cash and cash equivalents, investments in marketable securities and related interest receivable are not allocated to individual segments.

6. GOODWILL

We account for goodwill under the provisions of SFAS No. 142, “Goodwill and Other Intangible Assets.” We test goodwill for impairment using a discounted cash flow model. The technique used to determine the fair value of our reporting units is sensitive to estimates and assumptions associated with cash flow from operations and its growth, discount rates, and reporting unit terminal values. If these estimates or their related assumptions change in the future, we may be required to record impairment charges, which could adversely impact our operating results for the period in which such a determination is made. We perform our annual impairment evaluation of goodwill during the fourth quarter of each year and as changes in facts and circumstances indicate impairment exists.

6


Table of Contents

HEALTHSTREAM, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

6. GOODWILL (continued)

There have been no changes in the carrying amount of goodwill since December 31, 2003. The changes in the carrying amount of goodwill for the three months ended March 31, 2004 and 2003 are as follows:

                         
    HCO
  PMD
  Total
Balance at January 1, 2004
  $ 1,982,961     $ 1,323,727     $ 3,306,688  
Changes in carrying value of goodwill
                 
 
   
 
     
 
     
 
 
Balance at March 31, 2004
  $ 1,982,961     $ 1,323,727     $ 3,306,688  
 
   
 
     
 
     
 
 
                         
    HCO
  PMD
  Total
Balance at January 1, 2003
  $ 1,982,961     $ 1,323,727     $ 3,306,688  
Changes in carrying value of goodwill
                 
 
   
 
     
 
     
 
 
Balance at March 31, 2003
  $ 1,982,961     $ 1,323,727     $ 3,306,688  
 
   
 
     
 
     
 
 

7. INTANGIBLE ASSETS

All identifiable intangible assets have been evaluated in accordance with SFAS No. 142 and are considered to have finite useful lives. These intangible assets are being amortized over their estimated useful lives, ranging from one to five years. Amortization of intangible assets was $94,346 and $387,405 for the three months ended March 31, 2004 and 2003, respectively.

Identifiable intangible assets are comprised of the following:

                                                 
    As of March 31, 2004
  As of December 31, 2003
            Accumulated                   Accumulated    
    Gross Amount
  Amortization
  Net
  Gross Amount
  Amortization
  Net
Content
  $ 3,500,000     $ (3,125,000 )   $ 375,000     $ 3,500,000     $ (3,050,000 )   $ 450,000  
Customer lists
    2,940,000       (2,940,000 )           2,940,000       (2,930,278 )     9,722  
Other
    422,142       (381,206 )     40,936       422,142       (371,582 )     50,560  
 
   
 
     
 
     
 
     
 
     
 
     
 
 
Total
  $ 6,862,142     $ (6,446,206 )   $ 415,936     $ 6,862,142     $ (6,351,860 )   $ 510,282  
 
   
 
     
 
     
 
     
 
     
 
     
 
 

Estimated amortization expense for the periods and years ending December 31, is as follows:

         
April 1, 2004 through December 31, 2004
  $ 249,724  
2005
    166,212  
 
   
 
 
Total
  $ 415,936  
 
   
 
 

8. CONTINGENCIES

We are subject to various legal proceedings and claims that may arise in the ordinary course of business. In the opinion of management, the ultimate liability with respect to those proceedings and claims will not materially affect our financial position or results of operations.

9. SUBSEQUENT EVENTS

On April 28, 2004, our Vice Chairman, Jeffrey C. McLaren repaid the outstanding balance of the note receivable – related party and all accrued interest. In connection with this repayment, the Company and Mr. McLaren terminated the related stock pledge agreement.

On May 6, 2004, we signed two contracts with Tenet Healthcare Corporation (Tenet), where, under the first contract, Tenet will license our HealthStream Learning Center™ (HLC). The first contract extends through December 2005 and thereafter through a series of four annual renewable periods. In the second contract, we will provide courseware maintenance services for Tenet’s courseware library through May 2007 and thereafter through four annual, renewable periods. Annualized revenues under the agreements will vary based on Tenet’s employee census and the additional services that they may select.

7


Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Special Cautionary Notice Regarding Forward-Looking Statements

This Quarterly Report includes various forward-looking statements that are subject to risks and uncertainties. Forward-looking statements include without limitation, statements preceded by, followed by, or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates” or similar expressions. For those statements, HealthStream, Inc. claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

The following important factors, in addition to those discussed elsewhere in this Quarterly Report, could affect our future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in this document:

    our relatively short operating history;
 
    variability and length of our sales cycle;
 
    our ability to effectively implement our growth strategy, as well as manage growth of our operations and infrastructure;
 
    the market for online training and continuing education is relatively new and still evolving;
 
    our ability to adequately address our customers’ needs in products and services;
 
    the pressure on healthcare organizations and pharmaceutical/medical device companies could result in financial pressures on customers to cut back on our services;
 
    our ability to maintain and continue our competitive position against current and potential competitors;
 
    our ability to develop enhancements to our existing products and services, achieve widespread acceptance of new features, or keep pace with technological developments;
 
    our ability to obtain proper distribution rights from content partners to support growth in courseware subscriptions;
 
    our ability to achieve acceptable profitability results;
 
    fluctuations in quarterly operating results caused by a variety of factors including the timing of sales, subscription revenue recognition and customer subscription renewals;
 
    loss of a significant customer;
 
    our ability to adequately develop and maintain our network infrastructure and computer systems and software;
 
    the effect of governmental regulation on us, our business partners and our customers, including, without limitation, changes in federal, state and international laws or other regulations regarding education, training and Internet transactions; and
 
    other risk factors detailed in our Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

Overview and Critical Accounting Policies and Estimates

HealthStream was incorporated in 1990 and began marketing its Internet-based solutions in March 1999. The Company focuses on being a facilitator of training tools for entities in the healthcare industry. Revenues from the healthcare organizations business unit (HCO) are derived from the following categories: provision of services through our Internet-based learning products, courseware subscriptions, workforce development tools and services, maintenance and support of installed learning management products and a variety of online products. Revenues from the pharmaceutical and medical device company business unit (PMD) are derived from live event development, content development, Web cast events, and other educational and training services.

8


Table of Contents

Our condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). These accounting principles require us to make certain estimates, judgments and assumptions during the preparation of our financial statements. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements, as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected.

The accounting policies and estimates that we believe are the most critical in fully understanding and evaluating our reported financial results include the following:

    Revenue recognition
 
    Product development costs and related capitalization
 
    Goodwill, intangibles, and other long-lived assets
 
    Allowance for doubtful accounts

In many cases, the accounting treatment of a particular transaction is specifically dictated by GAAP and does not require management’s judgment in its application. There are also areas in which management’s judgment in selecting among available alternatives would not produce a materially different result. See Notes to Consolidated Financial Statements in our Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission, which contains additional information regarding our accounting policies and other disclosures required by GAAP. There have been no changes in our critical accounting policies and estimates from those reported in our Annual Report on Form 10-K for the year ended December 31, 2003.

Revenues and Expense Components

The following descriptions of the components of revenues and expenses apply to the comparison of results of operations.

Revenues. Revenues for our HCO business unit currently consist of the provision of services through our Internet-based learning products, including authoring tools, maintenance and support services for our installed learning management products, competency tools and courseware subscriptions. Revenues for our PMD business unit consist of live event development, custom online development, web cast events, live educational activities for nurses and technicians conducted within healthcare organizations and exhibit floor continuing education activities at association meetings.

Cost of Revenues. Cost of revenues consists primarily of salaries and employee benefits, employee travel and lodging, materials, contract labor, hosting costs, and other direct expenses associated with revenues as well as royalties paid by us to content providers based on a percentage of revenues. Personnel costs within cost of revenues are associated with individuals that provide services, handle customer support calls or inquiries, manage our web sites and content delivery and provide training or implementation services.

Product Development. Product development expenses consist primarily of salaries and employee benefits, third-party content acquisition costs, costs associated with the development of content and expenditures associated with maintaining, developing and operating our training delivery and administration platforms. In addition, product development expenses are associated with the development of new

9


Table of Contents

products and feature enhancements. Personnel costs within product development include our systems team, product managers, and other personnel associated with content and product development.

Sales and Marketing Expenses. Sales and marketing expenses consist primarily of salaries, commissions and employee benefits, employee travel and lodging, advertising, promotions, and related marketing costs. Personnel costs within sales and marketing include our sales and marketing team as well as our account management group.

Depreciation and Amortization. Depreciation and amortization consist of fixed asset depreciation, amortization of intangibles considered to have definite lives, amortization of content or license fees, prepaid compensation, and royalties paid to content providers that are of a fixed nature.

Other General and Administrative Expenses. Other general and administrative expenses consist primarily of salaries and employee benefits, employee travel and lodging, facility costs, office expenses and fees for professional services. Personnel costs within general and administrative expenses include individuals associated with normal corporate functions (accounting, legal, human resources, administrative and executive management) as well as accreditation professionals.

Other Income/Expense. The primary component of other income is interest income related to interest earned on cash, cash equivalents and investments in marketable securities. The primary component of other expense is interest expense related to capital leases and other obligations.

Recent Developments

On May 6, 2004, we signed two contracts with Tenet Healthcare Corporation (Tenet), where, under the first contract. Tenet will license our HealthStream Learning CenterTM (HLC). The first contract extends through December 2005 and thereafter through a series of four annual renewable periods. In the second contract, we will provide courseware maintenance services for Tenet’s courseware library through May 2007 and thereafter through four annual, renewable periods. We estimate the annualized revenues under both agreements will range between $1.25 - $1.50 million, based on Tenet’s employee census and the additional services that they may select. Approximately two-thirds of the revenues are related to HLC services, with the remainder derived from coursware maintenance services.

Results of Operations

During the three months ended March 31, 2004, we achieved record quarterly revenues of $4.9 million, which were up 11% over the prior year quarter. The growth in revenues was led by our flagship product, the HealthStream Learning Center, where we added over 60,000 fully implemented subscribers during the first quarter, bringing our fully implemented subscriber base to over 830,000 at March 31, 2004. In addition, content development revenues posted a significant increase. Gross margins for the first quarter 2004 declined as compared to the first quarter 2003 as a result of changes in product mix, primarily increases in content development, which have lower gross margins than our Internet-based products. Net loss also improved over the prior year quarter primarily related to increased revenues, reductions in product development and administrative personnel and reductions in depreciation and amortization.

Three Months Ended March 31, 2004 Compared to Three Months Ended March 31, 2003

Revenues. Revenues increased approximately $0.5 million, or 11.1%, from $4.4 million for the three months ended March 31, 2003 to $4.9 million for the three months ended March 31, 2004. Revenues for 2004 consisted of $3.2 million for HCO and $1.7 million for PMD. In 2003, revenues consisted of $2.9 million for HCO and $1.5 million for PMD. The increase in HCO revenues related primarily to growth in our Internet-based HealthStream Learning Center™ subscriber base of $0.4 million. Our subscriber base increased approximately 28%, from approximately 650,000 fully implemented subscribers at March 31, 2003 to approximately 831,000 fully implemented subscribers at March 31, 2004. This HCO revenue increase was partially offset by an anticipated decline in revenues from maintenance and support fees associated with our installed learning management products of approximately $0.1 million. Revenues from our Internet-based subscription products represented approximately 60% of total net revenues for the three months ended March 31, 2004 compared to 55% of total net revenues for the three months ended March 31, 2003. PMD revenues increased approximately $0.2 million, consisting of a $0.3 million increase in content development, which was partially offset by declines in live events and other online content.

We expect revenues from our installed learning management products, which are reaching the end of their life cycles, to decline for the remainder of 2004 as the customers using these products either transition to our Internet-based learning platform, or choose an alternative training solution. We also anticipate declines in live event revenues from historical levels for the remainder of 2004 due to several PMD customers adopting cautious positions with respect to the Office of Inspector General (OIG) guidelines and AdvaMed’s “Code of Ethics for Interactions with Healthcare Professionals” approved in September 2003 and effective January 1, 2004. Collectively, these guidelines placed additional regulations on the commercial support of educational activities.

Cost of Revenues. Cost of revenues increased approximately $0.4 million, or 26.4%, to $1.9 million for the three months ended March 31, 2004 from $1.5 million for the three months ended March 31, 2003. Cost of revenues as a percentage of revenues increased to 38.5% of revenues for the three months ended March 31, 2004 from 33.9% of revenues for the three months ended March 31, 2003. The increase in cost of revenues primarily related to personnel increases associated with our new Competency Compass and HospitalDirect products. We also experienced increased contract labor costs resulting from the increases in content development revenues discussed above.

Cost of revenues for HCO increased approximately $0.2 million and approximated 20.3% and 17.2% of revenues for the three months ended March 31, 2004 and 2003, respectively. Cost of revenues as a percentage of revenues increased due to the increases in personnel expense for Competency Compass discussed above, as well as increased royalties paid by us and increased costs associated with an additional hosting facility. During the three months ended March 31, 2004 we added a second hosting facility in Nashville, TN. Cost of revenues for PMD increased approximately $0.2 million and approximated 64.5% and 56.8% of revenues for the three months ended March 31, 2004 and 2003, respectively. Cost of revenues as a percentage of revenues for PMD increased as a result of personnel increases associated with HospitalDirect and higher contract labor costs associated with content development. We expect quarter-to-quarter fluctuations in cost of revenues for PMD due to the seasonality in live event and association activities and the variability related to our content development services.

Gross Margin. Gross margin (which we define as revenues less cost of revenues divided by revenues) declined from approximately 66.1% for the three months ended March 31, 2003 to 61.5% for the three months ended March 31, 2004. The decrease is a result of the change in

10


Table of Contents

revenue mix and related cost of revenues discussed above. Gross margins for HCO were 79.7% and 82.8% for the three months ended March 31, 2004 and 2003, respectively. Gross margins for PMD were 35.5% and 43.2% for the three months ended March 31, 2004 and 2003, respectively.

Product development. Product development expenses decreased approximately $0.3 million, or 32.3%, from approximately $1.0 million for the three months ended March 31, 2003 to approximately $0.7 million for the three months ended March 31, 2004. Product development expenses as a percentage of revenues decreased from 21.6% for the three months ended March 31, 2003 to 13.2% of revenues for the three months ended March 31, 2004. The decrease as a percentage of revenues primarily relates to the redesignation of personnel associated with Competency Compass and HospitalDirect to cost of revenues, as well as the increase in revenues discussed above.

Product development expenses for HCO decreased slightly compared to 2003 and approximated 16.5% and 20.0% of revenues for the three months ended March 31, 2004 and 2003, respectively. The percentage decrease is attributable to increases in HCO revenues, partially offset by changes in personnel associated with Competency Compass to cost of revenues. Product development expenses for PMD decreased approximately $0.2 million and approximated 4.9% and 18.3% of revenues for the three months ended March 31, 2004 and 2003, respectively. The decrease is primarily associated with the redesignation of personnel associated with HospitalDirect to cost of revenues, and reductions in the development of other content products. The unallocated corporate portion of our product development expenses decreased approximately $0.1 million, or 66.2%, as a result of a shift to projects that benefit the platform for both the HCO and PMD business unit products.

Sales and Marketing Expenses. Sales and marketing expenses, including personnel costs, were comparable between periods, and approximated 23.6% and 25.6% of revenues for the three months ended March 31, 2004 and 2003, respectively.

Sales and marketing expense for HCO were comparable between periods and approximated 25.5% and 28.9% of revenues for the three months ended March 31, 2004 and 2003, respectively. The percentage decreased due to the increases in HCO revenues. HCO marketing and advertising expenses, excluding personnel, decreased slightly as compared to the same period of 2003 due to reduced spending on marketing campaigns, which were offset by increases related to our e-learning Summit, held March 31 thru April 2, 2004. Sales and marketing expense for PMD were comparable between periods, and approximated 16.5% and 17.4% of revenues for the three months ended March 31, 2004 and 2003, respectively. The decrease primarily resulted from increased PMD revenues. PMD experienced higher commission expense during 2004, which was partially offset by reductions in personnel and related travel expenses.

Depreciation and Amortization. Depreciation and amortization decreased approximately $0.4 million, or 45.6%, from $0.9 million for the three months ended March 31, 2003 to $0.5 million for the three months ended March 31, 2004. Amortization declined $0.3 million as a result of certain intangible assets and prepaid content becoming fully amortized. Depreciation expense decreased $0.1 million due to certain assets becoming fully depreciated.

Other General and Administrative. Other general and administrative expenses decreased approximately $0.2 million, or 16.0%, from $1.4 million for the three months ended March 31, 2003 to $1.2 million for the three months ended March 31, 2004. Other general and administrative expenses as a percentage of revenues decreased from 32.2% for the three months ended March 31, 2003 to 24.3% for the three months ended March 31, 2004. The percentage decrease is a result of the revenue increases discussed above and reductions in administrative personnel.

Other general and administrative expenses for both HCO and PMD were comparable between periods. Other general and administrative expenses for the unallocated corporate functions decreased approximately $0.2 million, and approximated $1.1 million and $1.3 million for the three months ended March 31, 2004 and 2003, respectively. This decrease is primarily related to reductions in personnel.

Other Income/Expense. Other income/expense decreased approximately $70,000, or 59.7%, from approximately $120,000 for the three months ended March 31, 2003 to $50,000 for the three months ended March 31, 2004. The decrease resulted from lower interest income from investments in marketable securities due to lower invested balances.

Net Loss. Net loss decreased approximately $1.0 million, or 69.2%, from $1.4 million for the three months ended March 31, 2003 to $0.4 million for the three months ended March 31, 2004 due to the factors mentioned above.

11


Table of Contents

Liquidity and Capital Resources

Since our inception, we have financed our operations largely through proceeds from our initial public offering, private placements of equity securities, loans from related parties and, to an increasing extent, from revenues generated from the sale of our products and services.

Net cash used in operating activities was approximately $0.2 million during the three months ended March 31, 2004 compared to $0.7 million during the three months ended March 31, 2003. The improvement over the prior year quarter was primarily related to the decline in net loss of $1.0 million. Accounts receivable collection days also improved over the prior year quarter, approximating 55 days for the three months ended March 31, 2004 compared to 74 days for the three months ended March 31, 2003. The Company calculates days sales outstanding by dividing the accounts receivable balance (excluding unbilled and other receivables) by average daily revenues for the period. The primary use of cash in operating activities during the three months ended March 31, 2004 related to funding operations and purchases of content. During the three months ended March 31, 2003, the primary use of cash related to funding operations and the payment of bonuses to employees.

Net cash used in investing activities was approximately $0.2 million during the three months ended March 31, 2004 compared to approximately $3.2 million provided by investing activities for the three months ended March 31, 2003. The primary use of cash during the three months ended March 31, 2004 resulted from the acquisitions of property and equipment of approximately $635,000 offset by $400,000 in net proceeds from the sale and maturity net of purchases of investments in marketable securities. Property and equipment acquisitions primarily related to hardware and software for our second hosting facility in Nashville, TN. During the three months ended March 31, 2003, we received proceeds of $3.5 million from the maturity of investments in marketable securities, offset by $0.3 million in property and equipment acquisitions.

Cash used in financing activities was approximately $20,000 for the three months ended March 31, 2004 and $30,000 for the three months ended March 31, 2003. The use of cash during the three months ended March 31, 2004 and 2003 was primarily related to payments under capital lease obligations.

As of March 31, 2004, our primary source of liquidity was $16.8 million of cash and cash equivalents, restricted cash, investments in marketable securities, and interest receivable. We have no bank credit facility or other indebtedness other than capital lease obligations. As of April 30, 2004 we had cash and cash equivalents, restricted cash, investments in marketable securities, and interest receivable of approximately $16.5 million.

On April 28, 2004, our Vice Chairman, Jeffrey C. McLaren repaid the outstanding balance of the note receivable—related party and all accrued interest. In connection with this repayment, the Company and Mr. McLaren terminated the related stock pledge agreement.

We believe that our existing cash and cash equivalents, restricted cash, investments in marketable securities, and related interest receivable will be sufficient to meet anticipated cash needs for working capital, new product development and capital expenditures for at least the next 12 months. Our growth strategy may also include acquiring companies that complement our products and services. We anticipate that these acquisitions, if any, will be effected through a combination of stock and cash consideration. The issuance of stock as consideration for an acquisition could have a dilutive effect on our stock price. Failure to generate sufficient cash flow from operations or raise additional capital when required during or following that period in sufficient amounts and on terms acceptable to us could harm our business, financial condition and results of operations.

Commitments and Contingencies

We expect that capital expenditures will approximate $2.0 million during the remainder of 2004.

Our strategic alliances have typically provided for payments to content and distribution partners and development partners based on revenues, and we expect to continue similar arrangements in the future. We have capital lease obligations and operating lease commitments for our operating facilities in Nashville, TN and Denver, CO, and closed facilities in Dallas, TX and Raleigh, NC. Other than scheduled payments there have been no material changes in the future anticipated payments for our commitments and other contractual obligations from that reported in our Annual Report on Form 10-K for the year ended December 31, 2003.

12


Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to market risk from changes in interest rates. We do not have any commodity price risk. As of March 31, 2004, we had no outstanding indebtedness other than approximately $22,000 of capital lease obligations. Accordingly, we are not exposed to significant market risk. We are exposed to market risk with respect to the cash and cash equivalents and marketable securities in which we invest. At April 30, 2004, we had approximately $16.5 million of cash and cash equivalents, restricted cash, investments in marketable securities, and accrued interest that were invested in a combination of short term investments. Current investment rates of return approximate 1-2%. Assuming a 1.5% rate of return on $16.5 million, a hypothetical 10% decrease in interest rates would decrease interest income and increase net loss on an annualized basis by approximately $25,000.

We manage our investment risk by investing in corporate debt securities, foreign corporate debt and secured corporate debt securities with minimum acceptable credit ratings. For certificates of deposit and corporate obligations, ratings must be A2/A or better; A1/P1 or better for commercial paper; A2/A or better for taxable or tax advantaged auction rate securities and AAA or better for tax free auction rate securities. We also require that all securities must mature within 24 months from the original settlement date, the average portfolio shall not exceed 18 months, and the greater of 10% or $5.0 million shall mature within 90 days. Further, our investment policy also limits concentration exposure and other potential risk areas.

The above market risk discussion and the estimated amounts presented are forward-looking statements of market risk assuming the occurrence of certain adverse market conditions. Actual results in the future may differ materially from those projected as a result of actual developments in the market.

Item 4. Controls and Procedures

Evaluation of Controls and Procedures

HealthStream’s chief executive officer and principal financial officer have reviewed and evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of the end of the period covered by this quarterly report. Based on that evaluation, the chief executive officer and principal financial officer have concluded that HealthStream’s disclosure controls and procedures effectively and timely provide them with material information relating to HealthStream required to be disclosed in the reports it files or submits under the Exchange Act.

Changes in Internal Control Over Financial Reporting

There was no change in HealthStream’s internal control over financial reporting that occurred during the period covered by this quarterly report that has materially affected, or that is reasonably likely to materially affect, HealthStream’s internal control over financial reporting.

PART II - OTHER INFORMATION

Item 6. Exhibits and Reports on Form 8-K.

     (a) Exhibits

         
 
  31.1 -    Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
       
  31.2 -    Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
       
  32.1 -    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
       
  32.2 -    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

     (b) Reports on Form 8-K

       The Company furnished a report on Form 8-K on February 25, 2004 under Item 9 and Item 12 related to the results for the fourth quarter and full year ended December 31, 2003.
 
      Notwithstanding the foregoing, information furnished under Item 9 and Item 12 of the Company’s Current Reports on Form 8-K, including the related exhibits, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934.

13


Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
  HEALTHSTREAM, INC.
 
 
  By:   /s/ Arthur E. Newman    
    Arthur E. Newman   
    Chief Financial Officer
May 12, 2004
 

14


Table of Contents

HEALTHSTREAM, INC.

EXHIBIT INDEX

     
31.1
  Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
31.2
  Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
   
32.1
  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
   
32.2
  Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

15